Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study

Objectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Danilo Menichelli, Roberto Carnevale, Cristina Nocella, Vittoria Cammisotto, Valentina Castellani, Simona Bartimoccia, Giacomo Frati, Pasquale Pignatelli, Daniele Pastori
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
gut
Acceso en línea:https://doaj.org/article/9941436355da4b80bcc37ae8e215ba38
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9941436355da4b80bcc37ae8e215ba38
record_format dspace
spelling oai:doaj.org-article:9941436355da4b80bcc37ae8e215ba382021-11-17T05:26:05ZCirculating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study2297-055X10.3389/fcvm.2021.779503https://doaj.org/article/9941436355da4b80bcc37ae8e215ba382021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.779503/fullhttps://doaj.org/toc/2297-055XObjectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship between circulating lipopolysaccharides (LPS) and antioxidant status in AF patients.Patients and Methods:Post-hoc analysis from the ongoing prospective observational cohort ATHERO-AF study including 907 patients. Antioxidant status was evaluated by the activity of glutathione peroxidase 3 (GPx3) and superoxide dismutase (SOD). Patients were divided into two groups to evaluate the risk of CVEs: (1) LPS below median and GPx3 above median (n = 254); (2) LPS above median and GPx3 below median (n = 263).Results: The mean age was 73.5 ± 8.3 years, and 43.1% were women. Median LPS and GPx3 were 50.0 pg/ml [interquartile range (IQR) 15–108] and 20.0 U/ml (IQR 10.0–34.0), respectively. Patients of Groups 2 were older, with a higher prevalence of heart failure. LPS above the median was associated with reduced GPx3 [Odds Ratio for LPS 1.752, 95% Confidence Interval (CI) 1.344–2.285, p < 0.001] and SOD (OR 0.525, 95%CI 0.403–0.683) activity after adjustment for CHA2DS2VASc score. In a mean follow-up of 54.0 ± 36.8 months, 118 CVEs occurred, 42 in Group 1 and 76 in Group 2 (Log-Rank test p = 0.001). At multivariable Cox regression analysis, Group 2 was associated with a higher risk of CVEs [Hazard Ratio (HR) 1.644, 95%CI 1.117–2,421, p = 0.012], along with age ≥ 75 years (HR 2.035, 95%CI 1.394–2.972, p < 0.001), diabetes (HR 1.927, 95%CI 1.280–2.900, p = 0.002), and previous cerebrovascular disease (HR 1.895, 95%CI 1.251–2.870, p = 0.003) and previous cardiovascular disease (HR 1.708, 95%CI 1.149–2.538, p = 0.008).Conclusions: Our study indicates that circulating LPS may contribute to impaired antioxidant status in patients with AF. Patients with coincidentally high LPS and reduced GPx3 activity showed the highest risk of CVEs.Danilo MenichelliRoberto CarnevaleRoberto CarnevaleCristina NocellaCristina NocellaVittoria CammisottoValentina CastellaniSimona BartimocciaGiacomo FratiGiacomo FratiPasquale PignatelliPasquale PignatelliDaniele PastoriFrontiers Media S.A.articleatrial fibrillationlipopolysaccharidesglutathione peroxidasesuperoxide dismutaseantioxidantgutDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution DOAJ
collection DOAJ
language EN
topic atrial fibrillation
lipopolysaccharides
glutathione peroxidase
superoxide dismutase
antioxidant
gut
Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle atrial fibrillation
lipopolysaccharides
glutathione peroxidase
superoxide dismutase
antioxidant
gut
Diseases of the circulatory (Cardiovascular) system
RC666-701
Danilo Menichelli
Roberto Carnevale
Roberto Carnevale
Cristina Nocella
Cristina Nocella
Vittoria Cammisotto
Valentina Castellani
Simona Bartimoccia
Giacomo Frati
Giacomo Frati
Pasquale Pignatelli
Pasquale Pignatelli
Daniele Pastori
Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
description Objectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship between circulating lipopolysaccharides (LPS) and antioxidant status in AF patients.Patients and Methods:Post-hoc analysis from the ongoing prospective observational cohort ATHERO-AF study including 907 patients. Antioxidant status was evaluated by the activity of glutathione peroxidase 3 (GPx3) and superoxide dismutase (SOD). Patients were divided into two groups to evaluate the risk of CVEs: (1) LPS below median and GPx3 above median (n = 254); (2) LPS above median and GPx3 below median (n = 263).Results: The mean age was 73.5 ± 8.3 years, and 43.1% were women. Median LPS and GPx3 were 50.0 pg/ml [interquartile range (IQR) 15–108] and 20.0 U/ml (IQR 10.0–34.0), respectively. Patients of Groups 2 were older, with a higher prevalence of heart failure. LPS above the median was associated with reduced GPx3 [Odds Ratio for LPS 1.752, 95% Confidence Interval (CI) 1.344–2.285, p < 0.001] and SOD (OR 0.525, 95%CI 0.403–0.683) activity after adjustment for CHA2DS2VASc score. In a mean follow-up of 54.0 ± 36.8 months, 118 CVEs occurred, 42 in Group 1 and 76 in Group 2 (Log-Rank test p = 0.001). At multivariable Cox regression analysis, Group 2 was associated with a higher risk of CVEs [Hazard Ratio (HR) 1.644, 95%CI 1.117–2,421, p = 0.012], along with age ≥ 75 years (HR 2.035, 95%CI 1.394–2.972, p < 0.001), diabetes (HR 1.927, 95%CI 1.280–2.900, p = 0.002), and previous cerebrovascular disease (HR 1.895, 95%CI 1.251–2.870, p = 0.003) and previous cardiovascular disease (HR 1.708, 95%CI 1.149–2.538, p = 0.008).Conclusions: Our study indicates that circulating LPS may contribute to impaired antioxidant status in patients with AF. Patients with coincidentally high LPS and reduced GPx3 activity showed the highest risk of CVEs.
format article
author Danilo Menichelli
Roberto Carnevale
Roberto Carnevale
Cristina Nocella
Cristina Nocella
Vittoria Cammisotto
Valentina Castellani
Simona Bartimoccia
Giacomo Frati
Giacomo Frati
Pasquale Pignatelli
Pasquale Pignatelli
Daniele Pastori
author_facet Danilo Menichelli
Roberto Carnevale
Roberto Carnevale
Cristina Nocella
Cristina Nocella
Vittoria Cammisotto
Valentina Castellani
Simona Bartimoccia
Giacomo Frati
Giacomo Frati
Pasquale Pignatelli
Pasquale Pignatelli
Daniele Pastori
author_sort Danilo Menichelli
title Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
title_short Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
title_full Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
title_fullStr Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
title_full_unstemmed Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
title_sort circulating lipopolysaccharides and impaired antioxidant status in patients with atrial fibrillation. data from the athero-af study
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/9941436355da4b80bcc37ae8e215ba38
work_keys_str_mv AT danilomenichelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT robertocarnevale circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT robertocarnevale circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT cristinanocella circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT cristinanocella circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT vittoriacammisotto circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT valentinacastellani circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT simonabartimoccia circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT giacomofrati circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT giacomofrati circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT pasqualepignatelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT pasqualepignatelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
AT danielepastori circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy
_version_ 1718425941807464448